Antibody Responses Predict Antigen Exposure | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Archive for the ‘Antibody Responses Predict Antigen Exposure’ Category

MabVax Therapeutics fully human monoclonal antibody HuMab 5B1

Posted in Antibody Responses Predict Antigen Exposure, Monoclonal antibody therapy, Uncategorized on December 14, 2015| Leave a Comment »

MabVax Therapeutics fully human monoclonal antibody HuMab 5B1

Reporter: Aviva Lev-Ari, PhD, RN

MabVax’s HuMab 5B1 antibody (“5B1”) we are referring to an antibody produced by an actual human in response to a vaccine constructed to elicit an antibody response to a specific cancer antigen.

Recently, a series of successful studies were conducted on 5B1 and presented at the 2015 World Molecular Imaging Conference (WMIC) in September. These experiments showed the remarkable utility of this antibody and what it can potentially become.

HuMab 5B1 Dual Therapeutic and Diagnostic Approach

Our dual approach to the development of HuMab 5B1 gives us the potential to penetrate a substantial pancreatic cancer imaging market independent of the development success of HuMab 5B1 as a therapeutic.

Application as an Antibody Drug Conjugate: We are collaborating with Heidelberg Pharma to test an ADC using our HuMab 5B1 antibody and Heidelberg’s linker and toxin technology in animal models of pancreatic cancer. The results of both the in vitro and in vivo experiments provide strong support for moving the program into further preclinical and eventually clinical development.

Sourced through Scoop.it from: www.mabvax.com

See on Scoop.it – Cardiovascular Disease: PHARMACO-THERAPY

Read Full Post »

Pfizer bets $1 billion on BioAtla Conditionally Active Biologics | BioAcceleration™ for Protein Therapeutics

Posted in Antibody Responses Predict Antigen Exposure, Biological Networks, Gene Regulation and Evolution, Innovation in Immunology Diagnostics, Virology on December 14, 2015| Leave a Comment »

Pfizer bets $1 billion on BioAtla Conditionally Active Biologics | BioAcceleration™ for Protein Therapeutics

Reporter: Aviva Lev-Ari, PhD, RN

SAN DIEGO, CA – December 8, 2015 – BioAtla® LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. (NYSE: PFE) to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla’s CAB platform and utilizing Pfizer’s proprietary antibody drug conjugate (ADC) payloads.

Under the agreement, BioAtla and Pfizer will each have a license to the other’s respective technology to pursue the development and commercialization of several CAB-ADC antibodies. Pfizer also gains an exclusive option to develop and commercialize BioAtla CAB antibodies that target CTLA4, a validated immuno-oncology target in humans. If successful, BioAtla’s technology would allow the selective targeting of CTLA4 expressed on immune cells localized in the tumor microenvironment. BioAtla and Pfizer are both eligible to receive milestone payments and royalties based on individual CAB-ADC antibody candidates developed and commercialized by the other party. Including the CTLA4 option and license, BioAtla is eligible to receive a potential total of more than $1.0 billion in up-front, regulatory and sales milestone payments as well as tiered marginal royalties reaching double digits on potential future product sales.

CAB-ADC antibodies aim to address the inherent limitations of current ADC antibody technology by actively binding to antigens expressed on tumor tissue-resident cancer cells, but not to the same antigens expressed on normal cells in non-diseased tissues. If successful, this approach would allow the preferential targeting of tumor tissues by ADCs, thereby increasing the efficacy-safety ratios of CAB-ADCs relative to their conventional counterparts. The use of CAB antibodies as payload delivery vehicles could dramatically increase the number of tumor-associated antigens that are addressable with ADC technology.

Sourced through Scoop.it from: bioatla.com

See on Scoop.it – Cardiovascular Disease: PHARMACO-THERAPY

Read Full Post »

Antibody found that fights MERS coronavirus

Posted in Antibody Responses Predict Antigen Exposure, coronavirus, Immunology, Infectious Disease & New Antibiotic Targets, Microbiology, Virology on August 8, 2015| Leave a Comment »

Antibody found that fights MERS coronavirus

Reporter: Aviva Lev-Ari, PhD, RN

An international team of researchers has found a MERS neutralizing antibody—a discovery that could perhaps lead to a treatment for people infected with the virus. In their paper published in Proceedings of the National Academy of Sciences, the team describes the study they undertook that led to the discovery and why they believe what they found might lead to both prevention and treatment for the oftentimes deadly disease.

Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an ailment that causes severe respiratory problems for those infected and has a high mortality rate. It is believed to have got its start in humans after jumping from camels (who got it from bats) somewhere in the Middle East but has subsequently been found in patients in many other places. The virus does not transmit from person to person very easily, thus the source of most infections is still not clear. To date MERS has killed more than 500 people in 26 countries since it was first identified back in 2012. The most recent outbreak has been taking place in South Korea.

Efforts to find a means of preventing people from falling prey to the virus or combating it in those afflicted have thus far failed. In this new effort, the researchers studied the immune response of a 49 year old male patient suffering from the condition, but whose immune system finally won out. In so doing, they were able to locate the specific antibody that they believe was instrumental in saving the man’s life—known as LCA60, it binds to the virus when it encounters it, preventing the virus from binding to CD26 receptor cells.

The researchers tested the antibody in mice (by both injection and inhalation) and found that doing so caused a steep reduction in the number of virus cells in the lungs. Notably, they found that they got nearly the same results whether the mice were given the antibody before or after they were infected. This suggests it might be possible to inject the antibody into people at risk to help them fight off the disease and also to use it as a treatment for those that already have it.

Sourced through Scoop.it from: medicalxpress.com

See on Scoop.it – Cardiovascular Disease: PHARMACO-THERAPY

Read Full Post »

Antibody shows promise as treatment for HIV

Posted in Adaptive Immune Response to Biomaterials and Tissue Repair, Antibody Responses Predict Antigen Exposure, Immunodiagnostics, Immunology, Infectious Disease & New Antibiotic Targets, Infectious Disease Immunodiagnostics, Viral diseases, Virology - Vector-borne DIsease on April 9, 2015| Leave a Comment »

Antibody shows promise as treatment for HIV

Aviva Lev-Ari, PhD, RN

Treating HIV with an antibody can reduce the levels of the virus in people’s bodies — at least temporarily, scientists report on 8 April in Nature1. The approach, called passive immunization, involves infusing antibodies into a person’s blood. Several trials are under way in humans, and researchers hope that the approach could help to prevent, treat or even cure HIV. The work is a milestone towards those goals, says Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases in Bethesda, Maryland. “This is an early study, but it’s a study with some impressive results,” he says.

Researchers tested four different doses of an HIV antibody called 3BNC117 in 29 people in the United States and Germany. Seventeen of the participants had HIV, and 15 of those were not taking antiretroviral (ARV) drugs at the time of the study. One infusion of the highest dose of antibody, given to 8 participants, cut the amount of virus in their blood by between 8 and 250 times for 28 days.

But much work remains to determine whether the approach can produce longer-lasting effects and whether it is practical for clinical use. Previous studies have shown that passive immunization can reduce levels of HIV in the blood of monkeys and mice, although the approach has not worked as well in humans2.

But the antibodies used in those earlier clinical tests were of an older generation that could not neutralize many different strains of HIV. Researchers have spent much of the past decade trying to find ‘broadly neutralizing’ antibodies that are more widely effective against the virus, and the 3BNC117 antibody belongs to this class.

The price of treatment with this approach is also a concern. Antibodies can cost thousands of dollars for each course of treatment, and the majority of people with HIV are in low- and middle-income countries, some of which are already fighting drug companies over the high cost of antibody medicines. “The practicality, utility and efficacy of this approach are hugely open questions,” says Mitchell Warren, executive director of AVAC, a global organization that advocates HIV prevention and is headquartered in New York City.

Source: www.nature.com

See on Scoop.it – Cardiovascular and vascular imaging

Read Full Post »

Higher-Order Structure Comparability: Case Studies of Biosimilar Monoclonal Antibodies

Posted in Antibody Responses Predict Antigen Exposure, Immunology, Immunotherapy, Synergistic Innate and Adaptive Immunotherapy on August 16, 2014| Leave a Comment »

Higher-Order Structure Comparability: Case Studies of BioSimilar Monoclonal Antibodies

Reporter: Larry H. Bernstein, MD, FCAP

DR ANTHONY MELVIN CRASTO, Worlddrugtracker

MAbs and antibody–drug conjugates (ADCs) are among the fastest growing biologic segments in development, with hundreds of candidates currently under clinical study.

read at

http://www.bioprocessintl.com/manufacturing/biosimilars/higher-order-structure-comparability/